Amanda Nizam, MD
@AmandaNizamMD
Followers
2K
Following
14K
Statuses
5K
GU Medical Oncologist @ClevelandClinic | Bladder, kidney, & prostate Ca | Tx-related toxicity | @ASCOTECAG & @GWSMHS alum | 🌎 citizen | Views my own | COI ⬇️
Cleveland, OH (🏠 DC/VA)
Joined January 2010
Looking forward to this educational event with outstanding colleagues! #GU25
We are back in SanFran for #GU25! Join us On Feb12th in person to discuss the current SoC & the data from #GU25 @ASCO ⭐️ Feb 12: 6-8PM @AmandaNizamMD @DrRosenbergMSK @ERPlimackMD @TiansterZhang @BraunMDPhD ✅ Register: #AdvInOnc25 #OncTwitter #gusm
1
6
40
RT @neerajaiims: Ab#666 @ASCO #GU25 👉Congrats @basneta16 @shilpaonc for rapid oral👉👉In @FoundationATCG 👉 Unique gen…
0
12
0
RT @nataliagandur: 🌟📢 @ASCO #GU25 | Abstract 769🌟 🔹 Neoadjuvant aMVAC + Pembro in non-UC MIBC: Promising results 👨⚕️ Authors: @RubenRaych…
0
8
0
RT @shilpaonc: Congrats @tompowles1 @PGrivasMDPhD @y_loriot @AndreaNecchi & entire TROPICS-04 team on getting the data out in @Annals_Onco…
0
9
0
RT @nataliagandur: 🌟📢 @ASCO #GU25 | Abstract #661 🔬 Neoadjuvant Durvalumab + Chemo in High-Risk Upper Tract Urothelial Carcinoma (UTUC): E…
0
6
0
RT @nataliagandur: 🌟📢 @ASCO #GU25 | Abstract #665 🔬 Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: High Response Rates! 📊 Key…
0
8
0
RT @nataliagandur: 🌟📢 @ASCO #GU25 | Abstract #664 🔬 EV-302 confirms superior efficacy of EV+P vs chemo in 1L la/mUC!🌟 @tompowles1 @shilpao…
0
6
0
RT @nataliagandur: 🌟📢 #ASCOGU25 | Abstract #662 🔬 FORAGER-1: FGFR3-selective inhibitor LY3866288 shows strong efficacy & tolerability in mU…
0
4
0
RT @UrologyTimes: @LauraBukavinaMD takes over our account on Friday 2/14 during #GU25! Follow along as she shares key bladder cancer data,…
0
4
0
RT @OncBrothers: See you tonight before #GU25 kicks off! How will this data change/reinforce our practice? - Bladder Ca - Prostate Ca -…
0
11
0
RT @tompowles1: TROPICS4 sacituzimab govitecan vs chemo in pretreated UC @Annals_Oncology OS & PFS HRs=0.86. RR 23 vs 14, but G3+ TRAE 67 v…
0
32
0
RT @nataliagandur: 📢 @ASCO #GU25 | Abstract #659 🔬 NIAGARA: Perioperative Durvalumab + NAC improves survival & pCR in MIBC! @tompowles1 @Ma…
0
22
0
RT @neerajaiims: Ab#21 @ASCO #GU25 by @Prof_Nick_James👉�ARPI + transdermal estrogen patches (tE2) vs ARPI + LHRHa in…
0
18
0
RT @neerajaiims: Ab#22 @ASCO #GU25 by @niazi_Dr7👉�Randomized ph2 study of MDT in oligometastatic CRPC #prostatecance…
0
33
0
RT @neerajaiims: Ab#147 @ASCO #GU25 by @AzadOncology👉�In the ph3 LIBERTAS trial in pts w/ mHSPC #prostatecancer (n=3…
0
28
0
RT @neerajaiims: Ab#664 @ASCO #GU25 by @tompowles1👉👉Update from ph3 EV-302 in pts w/ met urothelial carcinoma #blad…
0
24
0
RT @DrChoueiri: 4/ New ADC Alert: SHR-A2102 for advanced/mUC targeting nectin-4! 38.4% confirmed ORR w/38.7% confirmed PR in ADC-pretreate…
0
3
0
RT @DrChoueiri: 3/ HER2+ MIBC: Neoadjuvant DV + toripalimab with 63.6% pCR! 84.6% pCR in HER2 IHC 3+!! 89.5% EFS at 1 year=>Big potential f…
0
5
0
RT @DrChoueiri: BEST of @ASCO #GU25 and what to look for based on abstracts release today 2/10. Top 4 in Kidney/Prostate/Bladder Cancers: @…
0
24
0
RT @neerajaiims: Ab#658 @ASCO #GU25 by @MattMilowsky 👉 👉Ph3 CheckMate 274 trial of adj nivo vs. placebo in MIUC #bl…
0
18
0
RT @neerajaiims: Ab#17 @ASCO #GU25 by #LouiseEmmett👉�OS & HRQoL data from ENZA-p (ANZUP 1901) #prostatecancer👉Lu-177…
0
19
0